Lexeo Therapeutics (NASDAQ:LXEO – Get Free Report) announced its earnings results on Monday. The company reported ($0.78) EPS for the quarter, topping the consensus estimate of ($0.87) by $0.09, Zacks reports.
Lexeo Therapeutics Price Performance
Shares of LXEO opened at $4.44 on Wednesday. The company has a current ratio of 5.95, a quick ratio of 5.95 and a debt-to-equity ratio of 0.01. The company’s fifty day simple moving average is $4.12 and its 200 day simple moving average is $6.67. Lexeo Therapeutics has a 1-year low of $2.32 and a 1-year high of $19.50. The company has a market cap of $146.81 million, a price-to-earnings ratio of -1.41 and a beta of 3.85.
Wall Street Analysts Forecast Growth
A number of analysts have recently commented on the company. Royal Bank of Canada cut their price target on Lexeo Therapeutics from $24.00 to $20.00 and set an “outperform” rating on the stock in a report on Tuesday. Leerink Partners cut their target price on Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating on the stock in a research note on Monday. Finally, Chardan Capital reaffirmed a “buy” rating and set a $25.00 price target on shares of Lexeo Therapeutics in a research note on Tuesday. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Lexeo Therapeutics currently has a consensus rating of “Buy” and an average price target of $22.80.
About Lexeo Therapeutics
Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.
Further Reading
- Five stocks we like better than Lexeo Therapeutics
- Growth Stocks: What They Are, What They Are Not
- Healthy Energy Drinks? Celsius Holdings Building Out the Space
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Occidental’s Billion-Dollar Carbon Credit Plan Takes Shape
- How to Capture the Benefits of Dividend Increases
- Airship AI: Why This AI Penny Stock Is Poised for a Big Breakout
Receive News & Ratings for Lexeo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexeo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
